Commercial Care Management Program for Complex & Rare Conditions Launched...

Care Management Program for Complex & Rare Conditions Launched by Accredo

-

Evernorth, a subsidiary of the healthcare company Cigna, has recently launched a program aimed at providing personalized support and care for patients suffering from rare and complex diseases. The program, known as the Accredo Rare and Complex Therapeutic Resource Center, is a specialty pharmacy initiative focused on ensuring that patients with complex conditions can access the care they need.

The program will be staffed by a team of clinical pharmacists and nurses who specialize in managing complex therapies. The team will work closely with patients, healthcare providers, and payers to develop personalized treatment plans that cater to each patient’s unique needs.

The Accredo Rare and Complex Therapeutic Resource Center is not just focused on providing care management services, but also on providing educational resources and support services to help patients better understand their conditions and how to manage them. Patients will have access to a dedicated website with information on their conditions and treatment options, as well as a mobile app that allows them to track their medication use and receive appointment and refill reminders.

Patients with rare and complex diseases often find it challenging to access the care they need because many of these conditions are poorly understood. According to the National Institutes of Health, there are over 7,000 rare diseases that affect over 25 million people in the United States. The Accredo Rare and Complex Therapeutic Resource Center aims to help these patients get the care and support they need to manage their conditions effectively.

The program will also work closely with healthcare providers and payers to ensure patients have access to the necessary treatments and therapies. Accredo’s expertise in specialty pharmacy will enable healthcare providers and payers to navigate complex reimbursement and prior authorization processes required for these treatments.

Evernorth Health Services’ president of pharmacy, Matt Perlberg, said “Rare diseases continue to challenge our healthcare system, and for patients there are often very limited or very expensive therapy options available. When these medications come to market, they can be highly complex and have very strict handling requirements. Patients often need help not just receiving but also taking their medications.”

There will, however, be discounts on all options of treatment and a dose calculator tool can be used to confirm that the proper dosages are provided to patients.

The Accredo Rare and Complex Therapeutic Resource Center is a significant step forward in providing patients with rare and complex diseases with the care and support they need. With its personalized care management services, educational resources, and support services, the program has the potential to make a significant difference in the lives of patients suffering from these conditions.

The Accredo Rare and Complex Therapeutic Resource Center is a valuable initiative aimed at providing personalized support and care for patients with rare and complex diseases. The program’s focus on providing educational resources and support services can help patients better understand and manage their conditions. Additionally, the program’s work with healthcare providers and payers can help ensure that patients have access to the treatments and therapies they need to manage their conditions.

Avatar
+ posts

Latest news

Phase 2/3 of Athira Trial for Alzheimer’s Fails

Athira Pharma’s Phase 2/3 Alzheimer’s disease trial has ended in failure. The trial revealed that fosgonimeton performed no better...

Sanofi’s Tolebrutinib faces defeat in 2 out of 3 phase 3 MS trials

Sanofi has announced that tolebrutinib, a BTK inhibitor, failed in two out of three Phase 3 trials. Tolebrutinib was...

Illumina Gets Favorable Decision Regarding Grail Acquisition

In a decision expected to limit Brussels' merger authority, American gene sequencing firm Illumina prevailed in court against the...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you